L'Oréal S.A. (LOR:CA) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call shows mixed signals: a decline in net profit and cash flow, yet a positive outlook for market growth and efficiency gains through AI and SAP. The Q&A highlights positive market growth in Europe and China, but also notes disruptions in North Asia and lack of clarity on financial impacts of IT transformations. The overall sentiment is balanced, with both positive and negative aspects, leading to a neutral prediction for stock price movement.

Key Financial Performance

Like-for-like growth 4%, marking another year of market outperformance.

Gross margin 74.3%, a new all-time high, up 10 basis points from last year despite the adverse impact from tariffs.

Operating profit margin 20.2%, increased by 20 basis points, reaching this level for the first time.

Operating net cash flow EUR 7.2 billion, up almost 8%, implying cash conversion of over 100%.

Sales Increased by 1.3%. Foreign exchange had a negative 3.6% impact as the euro appreciated against key currencies. The change in scope of consolidation contributed a positive 0.9%.

Emerging markets growth 9.7%, contributing 17% of group sales and 40% of growth. SAPMENA-SSA grew 10.9%, Latin America was up 8.3%, and Europe grew 4.4%.

North America sales Increased 3.4%, with a strong finish at 4.5% in the second half.

North Asia sales Advanced 0.5%, with Mainland China growth accelerating from 1% to 5%.

Professional Products division growth 7.5%, supported by the ongoing boom in premium haircare.

Consumer Products division growth 3.5%, led by haircare and a sharp recovery in makeup in the second half.

Luxe division growth 2.8%, with momentum accelerating to 3.6% in the second half.

Dermatological Beauty division growth 5.5%, led by haircare and skincare.

Haircare category growth 12.9%, the most dynamic category driven by strong volume growth.

Fragrances category growth 10.4%, growing twice as fast as the market.

Makeup category growth 3.5%, with strong acceleration in the second half, especially in North America.

E-commerce sales EUR 13 billion, crossing the 30% threshold for the first time, an increase of 200 basis points from 2024.

Gross profit EUR 32.7 billion, up 1.5%, with a record high gross margin of 74.3%.

Research and innovation expenses Increased 1.9% to EUR 1.4 billion, equivalent to 3.1% of sales.

Advertising and promotion expenses Rose 1.2% to EUR 14.2 billion, or 32.2% of sales, stable versus last year.

Selling and administrative expenses Down 10 basis points at 18.8% of sales, reflecting continued discipline and cost control.

Operating profit EUR 8.9 billion, up 2.4%, with an operating margin increase of 20 basis points to 20.2%.

Net financial charge EUR 236 million.

Income tax EUR 2.2 billion, representing a rate of 24.3%. Including exceptional French tax and nonrecurring items, income tax was close to EUR 2.4 billion, representing a tax rate of 27.8%.

Net profit excluding nonrecurring items EUR 6.8 billion, with diluted earnings per share at EUR 12.71, up slightly compared to last year.

Net profit after nonrecurring items EUR 6.1 billion, down 4.4% versus the previous year.

Cash flow Decreased by 2.2% to EUR 8.3 billion.

Capital expenditure EUR 1.5 billion, 3.4% of sales, 40 basis points below last year.

Residual cash flow EUR 2.4 billion.

Net debt EUR 2.1 billion, with a gearing ratio of 5.9% and financial leverage at 0.2x based on an EBITDA of EUR 10.5 billion.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Innovation pipeline: The contribution from new launches more than doubled between the first and second half of 2025, with a record number of 725 patents filed. New products like Kerastase Gloss Absolu, Matrix Mega Sleek, and Medik8's rollout are expected to drive growth in 2026.

Acquisitions: Acquired Medik8, Color Wow, and Kering Beauty brands like Creed, Balenciaga, and Bottega Veneta, strengthening the portfolio in luxury and premium segments.

Longevity and skincare: Launched advanced skincare products like Lancome Longevity MD and Vichy's new collagen supplement, focusing on longevity and proactive skin health.

Emerging markets: Emerging markets contributed 17% of group sales and 40% of growth, with strong performances in Vietnam, Gulf countries, Mexico, and Brazil. China showed mid-single-digit growth.

E-commerce: E-commerce sales crossed EUR 13 billion, accounting for over 30% of total sales, with significant growth in SAPMENA and emerging markets.

Operational efficiencies: AI and tech integration improved marketing ROI, content creation, and research processes, reducing time-to-market by up to 40%. AI-powered tools like BETiq and CreAItech enhanced operational productivity.

IT transformation: Rolled out IT transformation covering 60% of operations by the end of 2025, with plans to expand further in 2026.

Sustainability: Reduced virgin plastic use by 37% since 2019 and achieved a AAA rating by CDP for the 10th consecutive year.

Portfolio diversification: Expanded into new categories like longevity and aesthetics through partnerships and acquisitions, including a JV with Kering and increased stake in Galderma.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Foreign Exchange Impact: The euro appreciated against key currencies, leading to a negative 3.6% impact on sales in 2025. If exchange rates remain constant, the impact on sales in 2026 is projected to be a negative 2.5%.

IT Transformation Rollout: The IT transformation rollout in 2026 will cover major clusters like the U.S., UK-Ireland, and Australia-New Zealand, potentially impacting divisional and regional growth numbers.

Travel Retail Asia: Continued softness in the travel retail market in Korea and Mainland China, along with disruptions like the suspension of the Sunrise app and changes in domestic airport operators, negatively impacted sales. Travel Retail Asia now accounts for less than 4% of total sales, down from over 6% three years ago.

Economic and Geopolitical Uncertainty: Growing economic and geopolitical uncertainty could impact consumer spending and market dynamics.

India Market Performance: India's performance did not meet expectations in 2025, leading to a new operational setup in the region for 2026.

CeraVe Turnaround Challenges: CeraVe faced challenges in the U.S. market, requiring a turnaround plan to regain momentum.

Skincare Market Dynamics: The skincare category underperformed in 2025, requiring changes in innovation and media strategies to meet L'Oreal's standards.

Tariffs and FX Context: Tariffs and unfavorable foreign exchange rates negatively impacted operating margins in 2025.

Emerging Markets: While emerging markets contributed significantly to growth, challenges in regions like India highlight the variability in performance across these markets.

Longevity and Aging Trends: The shift towards longevity and proactive skin health requires significant investment in research and innovation to stay competitive.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

IT Transformation: 2026 will be the most important year for IT transformation, covering the U.S., UK-Ireland, and Australia-New Zealand clusters. By the end of the year, 60% of the total IT transformation will be completed, up from 30% in 2025.

Regional Growth: Emerging markets are expected to continue spearheading growth, contributing significantly to group sales and growth. North Asia, particularly Mainland China, is anticipated to recover further, with growth driven by Luxe and other divisions.

Divisional Growth: Professional Products division aims to maintain growth momentum with innovations in haircare and styling, leveraging AI and tech for value creation. Consumer Products division plans to strengthen its brand portfolio and drive penetration in emerging markets. Dermatological Beauty division expects strong growth driven by health and longevity trends, dermo haircare, and emerging markets. L'Oreal Luxe anticipates market reacceleration, particularly in the U.S. and China, with a focus on innovation and regional expansion.

E-commerce: E-commerce is expected to remain a major growth engine, with its weight surpassing 30% of sales. Growth is anticipated across all regions, especially in emerging markets.

Innovation Pipeline: 2026 will see a strong innovation pipeline across all divisions, including new launches in haircare, skincare, makeup, and fragrances. AI and tech will play a significant role in driving innovation and operational efficiency.

Acquisitions and Portfolio Expansion: The company plans to leverage recent acquisitions like Medik8, Color Wow, and Kering Beauty to strengthen its competitive position and expand into new categories and markets.

Longevity and Skincare: The focus will be on bridging health and beauty, pioneering longevity science, and expanding into body care and supplements. New molecules and technologies are expected to drive growth in skincare.

Market Trends: The beauty market is expected to grow, driven by increasing consumer numbers, e-commerce penetration, price laddering, and the sophistication of beauty routines. Emerging markets and younger demographics are key growth areas.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

Dividend Increase: The Board of Directors proposed a 2.9% increase in the dividend to EUR 7.20 per share at the AGM.

Payout Ratio: The payout ratio is 56.6%, illustrating L'Oreal's consistent and dynamic dividend policy.

Share Buybacks: EUR 0.5 billion was spent on share buybacks in 2025.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:What is the market growth outlook for 2026, particularly in Europe and China?

A:The market is expected to grow faster in 2026 than in 2025, with a run rate of 4% to 4.5% in the second half of 2025. Europe shows no signs of slowdown, and the U.S. and China are performing well. Emerging markets remain dynamic, though there was a slowdown in Latin America at the end of 2025.

Q:What was the split between volume and price mix in 2025, and how should we think about the margin outlook for 2026?

A:In 2025, growth was driven 80% by value, with pricing and mix contributing positively. Tariffs are expected to have a slightly higher impact in 2026, but pricing and mix improvements, particularly in the Luxe division, will help maintain a high gross margin.

Q:What was the impact of Travel Retail in North Asia in Q4 2025, and what are the expectations for Q1 2026?

A:Travel Retail in North Asia faced disruptions in Q4 2025, with a mid-teens negative sell-in and flat sell-out. Inventory levels remain healthy, and the market is expected to be flattish in 2026. Restocking in Q1 2026 is anticipated.

Q:What are the expected efficiencies from AI and SAP implementation in 2026?

A:AI is being used for revenue growth management, advertising optimization, and SG&A reductions. Tools like BETiq and CREAITECH are improving ROI and reducing content creation costs by 40%. SAP implementation will continue to enhance productivity, but specific financial impacts for 2026 are not yet detailed.

Q:What could have been done better in 2025 to outperform the market, and what are the expectations for the Chinese ecosystem in 2026?

A:Skincare innovation was lacking in 2025, impacting growth. Adjustments have been made to improve innovation and engagement strategies. The Chinese ecosystem is improving, with luxury consumption rebounding and Travel Retail expected to recover. Growth in North Asia is anticipated to be driven by premium products.

Q:What is the outlook for Dermatological Beauty in 2026, and how will innovation be managed?

A:The dermatological market is expected to remain robust, with strong brand execution and limited exposure to drugstore channels. AI will play a key role in managing the speed and scale of innovation, reducing content creation costs and enhancing R&D efficiency.

Q:What is the potential for Kering Beauty licenses, and what is the governance outlook with Nestle?

A:The Kering Beauty licenses, including Creed, Bottega, and Balenciaga, have significant potential, with Creed expected to become a billion-euro brand. Nestle's proposed Board appointments reflect internal changes, and their long-term shareholder status is expected to continue.

Q:What are the plans for India and the Beauty Stimulus Plan in 2026?

A:India's growth was high single-digit in 2025 but lacked market share gains. A new strategic plan and leadership are in place to drive growth. The Beauty Stimulus Plan will be larger in 2026, focusing on accelerating innovation across all divisions and categories.

Q:What drove the strong performance in Europe in Q4 2025, and what is the outlook for haircare and hair color?

A:Europe's strong Q4 performance was broad-based across all divisions. Haircare grew double digits, while hair color was flat. Professional hair color is growing in emerging markets but soft in mature markets. Consumer Products Division is stimulating the market with innovation and engagement strategies.

Q:What is the impact of increasing the stake in Galderma, and what are the IT transformation plans for 2026?

A:Increasing the stake in Galderma allows L'Oreal to consolidate profits, participate in strategy discussions, and expand scientific partnerships. IT transformations, including AI and SAP, will enhance productivity and reduce SG&A costs, but specific impacts for 2026 are not yet detailed.

Q:What are the changing dynamics in the skincare market, particularly in Dermatological Beauty?

A:Consumers are seeking performance and trust, with dermatological beauty addressing these needs through science-backed products. The rise of AI and LLMs is enhancing brand visibility and trust, particularly for brands like La Roche-Posay and CeraVe.

Q:Review of Unclear Management Responses

A:Management avoided providing specific financial impacts of IT transformations and the exact scale of the Beauty Stimulus Plan for 2026. They also did not comment on the potential additional payment for an early termination of the Gucci license under Kering Beauty.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

CELC Transcript

L'Oréal S.A. (LOR:CA) Q4 2025 Earnings Call Transcript

Unknown2-13

Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript

Positive11-12

The earnings call highlights strong potential for gedatolisib with a $5 billion market opportunity and extended patent exclusivity. Despite increased losses due to higher R&D and operational costs, the company has a solid cash position to support future growth. The Q&A section indicates positive analyst sentiment and excitement around clinical trial progress and market strategy. While some details remain unclear, the overall outlook is promising, suggesting a positive stock price movement.

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Unknown8-15

The earnings call presents mixed signals: collaboration with renowned institutions and a solid cash position are positives, but increased losses and R&D expenses raise concerns. The Q&A revealed management's evasiveness on critical safety and competitive landscape details, which may dampen investor confidence. Despite potential in new drug trials, the lack of clear guidance and increased expenses suggest a neutral sentiment. Without market cap data, we assume a moderate reaction.

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

Unknown5-14

The earnings call reveals significant financial challenges, including increased net loss and operational expenses, without any share repurchase program to boost shareholder confidence. Despite optimistic market potential, regulatory and market adoption risks remain high. The Q&A section highlights management's reluctance to provide specific projections, which can increase investor uncertainty. No new partnerships or positive catalysts were announced. Overall, the financial outlook and management's evasive responses contribute to a negative sentiment, likely leading to a stock price decline in the range of -2% to -8%.

CELC Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.